Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 72,806 shares at $59.08 ($4.3M) on 2021-04-01, disclosed to the SEC on 2021-04-05.
Open-market sale of $4.3M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $58.42 | 3,790 | $221K | 5.1% |
| 2 | $58.42 | 3,790 | $221K | 5.1% |
| 3 | $58.42 | 2,472 | $144K | 3.3% |
| 4 | $58.42 | 2,472 | $144K | 3.3% |
| 5 | $59.08 | 1,533 | $91K | 2.1% |
| 6 | $59.08 | 1,533 |
| $91K |
| 2.1% |
| 7 | $59.08 | 2,350 | $139K | 3.2% |
| 8 | $60.82 | 283 | $17K | 0.4% |
| 9 | $60.82 | 434 | $26K | 0.6% |
| 10 | $61.36 | 134 | $8K | 0.2% |
| 11 | $61.36 | 206 | $13K | 0.3% |
| 12 | $58.66 | 195 | $11K | 0.3% |
| 13 | $58.66 | 298 | $17K | 0.4% |
| 14 | $59.76 | 3,551 | $212K | 4.9% |
| 15 | $59.76 | 3,551 | $212K | 4.9% |
| 16 | $59.76 | 5,445 | $325K | 7.5% |
| 17 | $59.76 | 5,445 | $325K | 7.5% |
| 18 | $60.26 | 6,972 | $420K | 9.7% |
| 19 | $60.26 | 6,972 | $420K | 9.7% |
| 20 | $60.26 | 10,690 | $644K | 14.8% |
| 21 | $60.26 | 10,690 | $644K | 14.8% |
| Total | $59.73 avg | 72,806 | $4.3M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |